Nasopharyngeal carcinoma

被引：295

作者：

Chan, ATC ^{[1
]}

Teo, PML ^{[1
]}

Johnson, PJ ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sir YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷 / 07期

关键词：

Epstein-Barr virus; nasopharyngeal carcinoma; review; treatment;

D O I：

10.1093/annonc/mdf179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal carcinoma (NPC) is endemic in southern China where genetic abnormalities and Epstein-Barr virus (EBV) infection are critical in the pathogenesis of the disease, Circulating EBV-DNA has been shown to improve prognostication and monitoring of NPC patients. Radiotherapy is the mainstay treatment for early disease and concurrent cisplatin/radiotherapy has been demonstrated to prolong survival in locoregionally advanced disease. Ongoing studies of targeting agents and immunotherapeutic approaches may further improve treatment results.

引用

页码：1007 / 1015

页数：9

共 61 条

[31]

Lo KW, 2000, CANCER RES, V60, P3348

[32]

Lo KW, 2001, CANCER RES, V61, P3877

[33]

Lo YMD, 1999, CANCER RES, V59, P1188

[34]

Lo YMD, 1999, CANCER RES, V59, P5452

[35]

Lo YMD, 2000, CANCER RES, V60, P6878

[36] Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma [J].

Ma, J ;

Mai, HQ ;

Hong, MH ;

Min, HQ ;

Mao, ZD ;

Cui, NJ ;

Lu, TX ;

Mo, HY .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1350-1357

[37]

Marks JE, 1998, CANCER, V83, P582, DOI 10.1002/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO

[38]

2-R

[39]

NGAN KC, 2001, P AM SOC CLIN ONCOL, V20

[40]

O'Sullivan B, 2001, PROGNOSTIC FACTORS C

← 1 2 3 4 5 6 7 →